Antibody rationale

Some 5-25 per cent of individuals suffering from haemophilia A develop anti-factor VIII antibodies, and 3-6 per cent of haemophilia B sufferers develop anti-factor IX antibodies. This complicates treatment of these conditions and, as mentioned previously, one approach to their treatment is direct administration of factor Vila. The therapeutic rationale is that factor Vila could directly activate the final common steps of the coagulation cascade, independently of either factor VIII or IX (Figure 12.1). Factor Vila forms a complex with tissue factor that, in the presence of phospholipids and Ca2+, activates factor X. 

Revillard, J.P., Robinet, E., Goldman, M., Bain. H.. Latinne, D. and Chatenoud, L. (1995) In vitro correlates of the acute toxic syndrome induced by some monoclonal antibodies a rationale for the design of predictive tests. Toxicology, 96. 51-58. 

Several clinical trials have evaluated (or continue to evaluate) monoclonal antibodies to which a radioactive tag has been conjugated. These are usually employed as potential anti-cancer agents. The rationale is selective delivery of the radioactivity directly to the tumour site. Most of the radioisotopes being evaluated are /i-emitters these include I and I (iodine), Re and Re (rhenium) and (yttrium). The medium-energy radioactivity these emit is capable of penetrating... 

Our rationale was that if SARS-CoV expressed antigenic carbohydrate structures, then immunizing animals using the whole virus-based vaccines would have elicited specific antibodies for these structures. In addition, if SARS-CoV displayed a carbohydrate structure that mimics host cellular glycans, then vaccinated animals may develop antibodies with autoimmune reactivity to their corresponding cellular glycans. 

In the present manuscript, we will discuss the mechanism by which endotoxin initiates the sepsis cascade, the rationale for targeting LPS, and the most significant treatments that have been studied antibodies, vaccines, binding peptides, lipid A analog, phospholipids, and polymyixin B hemoperfusion. 

Because the classical pathway has a requirement for polysaccharide-specific antibody, and because the process of producing this antibody takes a few days, the host is compromised during the initial, acute stages of bacterial infection, and is liable to die, or to acquire serious morbidity effects. Thus, the rationale behind vaccination with capsular polysaccharides is to maintain a long-lasting, effective level of polysaccharide-specific antibody in the host. 

PURPOSE AND RATIONALE Anti-insulin antibodies (ALA) develop in the serum of many patients who are receiving insulin treatment (Berson et al 1956). In addition, insulin auto antibodies (IAA) are detected in insulin dependent diabetes melhtus (IDDM) or Type I Diabetes before insulin therapy (Palmer et al 1986). 

---